ABSTRACT
<p><b>OBJECTIVE</b>To introduce a new method to correct ectropion following lower eyelid blepharoplasty.</p><p><b>METHODS</b>To expand the skin and tissue in the infra-orbital region of ectropion following lower eyelid blepharoplasty by using an expander (30-50 ml) from oral vestibulum. After 1-2 weeks, the ectropion could be corrected.</p><p><b>RESULTS</b>32 cases were all successful by using this methods.</p><p><b>CONCLUSION</b>It is a effective method expanding the skin and tissue in infra-orbital region by tissue expander to correct the ectropion following lower eyelid blepharoplasty.</p>
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Blepharoplasty , Ectropion , General Surgery , Postoperative Complications , General Surgery , Tissue Expansion DevicesABSTRACT
Objective To explore the clinical efficacy of photoreju ve nation in the treatment of face telangiectasias by intense pulsed light. Methods A total of 56 patients (age ranged from 27～39 years ) wh o suffered from telangiectasias were cured in this hospital since November 2001. Results All the cases were divided into three clinical grou ps: mild, intermediate and severe. After the treatment of 4 to 8 times, 17 patie nts were cured (30.4 %), 23 patients with significant improvement (41.0 %), 13 p atients with improvement (23.3 %), and no effect in 3 cases (5.3 %). Co nclusions Intense pulsed light is an excellent new technique for f ace telangiectasias. Correct operation parameters are important factors for sati sfactory clinical efficacy.
ABSTRACT
Objective: To evaluate the effect of platelet activating factor(PAF) antagonism on the blood content in the random survival flap. Methods: A lipophilic PAF receptor antagonist BN52021 was administered to treat flaps through a local subcutaneous injection route 30 min prior to transplantation. The flaps were imaged in situ by a gamma camera. Results: The PAF receptor antagonist significantly augmented the accumulation of radioactivity of middle and end part within treated flaps( P